Watch for insider selling or Form 4 filings by Galephar; the overhang may pressure the already low share price. The company's cash position remains critical.
Price Chart
Executive Summary
Ensysce Biosciences' S-3 registration statement (resale of 1,300,000 shares by selling securityholders) became effective on June 26, 2026. The company receives no proceeds, and the filing highlights its distressed financial position with going-concern and Nasdaq delisting risks.
Key Facts
- Effectiveness date: June 26, 2026
- Covers 1,300,000 shares for resale (1,280,000 to Galephar, 20,000 to consultant)
- Company receives no proceeds from resales
- Prior S-3 filing noted going-concern warning, Nasdaq delisting risk, and cash runway into late Q2 2026
Financial Impact
Potential selling pressure from resale of 1.3M shares; no capital raised for Ensysce
Risk Factors
- Further dilution from resale shares
- Nasdaq delisting if compliance not regained
- Limited cash runway constrains operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002133 |
| Document: 9999999995-26-002133-index.html | 9999999995-26-002133 |
| Document: 9999999995-26-002133.txt | 9999999995-26-002133 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | S-3 | $0.4847 | awaiting T+20 | — | $0.4710 (+2.83%) |
Aug 25, 2026 8w ago | 8-K | $0.4120 $0.4001 | ▲ +2.89% | ▲ +3.11% | $0.4710 (−14.32%) |
Jun 29, 2026 17w ago | EFFECT | $0.2967 $0.2614 | ▲ +11.90% | ▲ +11.62% | $0.4710 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers